Literature DB >> 30172026

Inhibition of mTORC2 enhances UVB-induced apoptosis in keratinocytes through a mechanism dependent on the FOXO3a transcriptional target NOXA but independent of TRAIL.

Robert P Feehan1, Amanda M Nelson2, Lisa M Shantz3.   

Abstract

The primary cause of non-melanoma skin cancer (NMSC) is ultraviolet B (UVB) radiation. We have shown previously that mTORC2 inhibition sensitizes keratinocytes to UVB-induced apoptosis mediated by the transcription factor FOXO3a. FOXO3a is a key regulator of apoptosis and a tumor suppressor in several cancer types. Activation of FOXO3a promotes apoptosis through the coordinated expression of a variety of target genes, including TRAIL and NOXA. We hypothesized that in the setting of mTORC2 inhibition, the UVB-induced expression of these factors would lead to apoptosis in a FOXO3a-dependent manner. Using spontaneously immortalized human keratinocytes (HaCaT cells), we observed that both TRAIL and NOXA expression increased in cells exposed to UVB and the TOR kinase inhibitor Torin 2. Similar to knockdown of FOXO3a, NOXA knockdown reversed the sensitization to UVB-induced apoptosis caused by mTORC2 inhibition. In contrast, loss of TRAIL by either knockdown or knockout actually enhanced expression of nuclear FOXO3a, which maintained apoptosis. These surprising results are not due to faulty death receptor signaling in HaCaT cells, as we found that the cells undergo extrinsic apoptosis in response to treatment with recombinant TRAIL. Even more striking, TRAIL knockout cells were sensitized to recombinant TRAIL-induced apoptosis compared to wild-type HaCaT cells, with the largest increase occurring in the presence of mTORC2 inhibition. Taken together, these studies provide strong evidence that mTORC2 controls UVB-induced apoptosis by regulating NOXA expression downstream of FOXO3a. Moreover, FOXO3a transcriptional activation by mTORC2 inhibitors may be a valuable target for prevention or therapy of NMSC, especially in cases with low endogenous TRAIL.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; NOXA; Non-melanoma skin cancer; TRAIL; UVB; mTOR

Mesh:

Substances:

Year:  2018        PMID: 30172026      PMCID: PMC6185741          DOI: 10.1016/j.cellsig.2018.08.018

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  60 in total

1.  An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4.

Authors:  Gregory S Yochum; Ryan Cleland; Shannon McWeeney; Richard H Goodman
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

2.  TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation.

Authors:  V K Puduvalli; D Sampath; J M Bruner; J Nangia; R Xu; A P Kyritsis
Journal:  Apoptosis       Date:  2005-01       Impact factor: 4.677

3.  Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Cell Signal       Date:  2016-04-04       Impact factor: 4.315

Review 4.  DNA damage response--a double-edged sword in cancer prevention and cancer therapy.

Authors:  Hui Tian; Zhen Gao; HuiZhong Li; BaoFu Zhang; Gang Wang; Qing Zhang; DongSheng Pei; JunNian Zheng
Journal:  Cancer Lett       Date:  2014-12-17       Impact factor: 8.679

Review 5.  Akt, FoxO and regulation of apoptosis.

Authors:  Xinbo Zhang; Naimei Tang; Timothy J Hadden; Arun K Rishi
Journal:  Biochim Biophys Acta       Date:  2011-03-31

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

Authors:  Naoko Seki; Uhi Toh; Thomas J Sayers; Teruhiko Fujii; Motoshi Miyagi; Yoshito Akagi; Jingo Kusukawa; Masayoshi Kage; Kazuo Shirouzu; Hideaki Yamana
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

Review 8.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

9.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

Review 10.  Onto better TRAILs for cancer treatment.

Authors:  D de Miguel; J Lemke; A Anel; H Walczak; L Martinez-Lostao
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

View more
  2 in total

1.  BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation.

Authors:  Yihong Zhan; Yue Wang; Miao Qi; Panpan Liang; Yu Ma; Ting Li; Hui Li; Congmei Dai; Zhifeng An; Yitao Qi; Hongmei Wu; Huanjie Shao
Journal:  Cell Biosci       Date:  2019-07-23       Impact factor: 7.133

2.  Sex-specific differences in patients with nonmelanoma skin cancer of the pinna.

Authors:  Ulrich Moser; Alexandros Andrianakis; Prisca Pondorfer; Axel Wolf; Matthias Graupp; Thomas Weiland; Clemens Holzmeister; Dominik Wild; Dietmar Thurnher
Journal:  Head Neck       Date:  2020-05-05       Impact factor: 3.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.